ETON Eton Pharmaceuticals

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced that it will report third quarter 2023 financial results on Thursday, November 9, 2023. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).

Register* (Audio Only)         

In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: .



The live webcast can be accessed on the Investors section of Eton’s website at . An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.

* Conference call participants should register to obtain their dial-in and passcode details. Please be sure to register using a valid email address.

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases. The Company currently has four FDA-approved rare disease products, ALKINDI SPRINKLE® for the treatment of pediatric adrenocortical insufficiency, Carglumic Acid for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency, Betaine Anhydrous for the treatment of homocystinuria, and Nitisinone for the treatment of hereditary tyrosinemia type 1. The Company has four additional product candidates in late-stage development: ET-400 for the treatment of adrenocortical insufficiency, ET-600 for the treatment of diabetes insipidus, ZENEO® hydrocortisone autoinjector for the treatment of adrenal crisis, and dehydrated alcohol injection for the treatment of methanol poisoning. For more information, please visit our website at .

Investor Relations:

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E:

Source: Eton Pharmaceuticals



EN
30/10/2023

Underlying

ETONEton Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eton Pharmaceuticals

 PRESS RELEASE
Free
ETON Eton Pharmaceut...

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows: The 25th Annual B. Riley Securities Investor ConferenceDate: Thursday, May 22, 2025, at ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
ETON Eton Pharmaceut...

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of p...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ETON Eton Pharmaceut...

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on...

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In* (Audio Only)         Webcast:           ...

May 1, 2025 1 EN
 PRESS RELEASE
Free
ETON Eton Pharmaceut...

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopres...

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-...

April 28, 2025 1 EN
 PRESS RELEASE
Free
ETON Eton Pharmaceut...

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

Eton Pharmaceuticals Out-Licenses International Rights to Increlex® Esteve Pharmaceuticals, S.A. will commercialize Increlex in all markets outside the U.S. DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”). “Esteve shares Eton’s dedication to putting patients first ...

April 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch